Business ❯ Finance ❯ Mergers and Acquisitions ❯ Pharmaceuticals

Alkermes and Avadel Pharmaceuticals

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Analysts say the richer bid pressures Alkermes to decide its next move.

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion